Protagenic gets FDA green light to submit IND for anxiety drug
The FDA raised no objections to Protagenic's plan for testing PT00114 for generalized anxiety disorder, with submission targeted for late 2026. The biotech shares advanced to a 'Clear Path' designation, significantly de-risking its next clinical phase.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day